RESEARCH ARTICLE Engaging GPs in insulin th t

Full list of author information is available at the end of the articleBackground Type 2 diabetes (T2DM) is characterized by both insulin resistance and inadequate insulin secretion. As T2DM is a progressive disease many patients require insulin ther-apy at some point in time [1]. The number of T2DM patients on insulin therapy is rising due to the increasing prevalence of T2DM, the more stringent glycaemic targets and improved life expectancy among T2DM patients. In 2004 396,481 persons in Belgium were reimbursed at least one package of diabetes medication of whom 104,780 were prescribed insulin therapy; in 2010 this was respect-ively 489,559 and 136,753 [2]. Although insulin therapy is no longer a secondary care based activity in countries like the United Kingdom (UK) and the Netherlands, the involvement of general practitioners (GPs) is still limited in many other coun-tries [3-5]. There is no evidence that the outcomes of in